Illustrative

The Current Role of Immune Checkpoint Inhibitors in Bladder Cancer

Urology Times·Oct 14

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

The role of immune checkpoint inhibitors in bladder cancer is being examined. The current state of their use in this context is a topic of discussion. The function and potential impact of these inhibitors in treating bladder cancer are under consideration.

Full coverage

Recent advances in immunotherapy for bladder cancer: mechanisms, clinical applications, and future perspectives

Frontiers·Mar 3

Targeted Therapies and Biomarker-Driven Therapy Advance MIBC Treatment Paradigm

OncLive·May 19

Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment

Frontiers·Oct 27

CREST and POTOMAC: Redefining immunotherapy’s role in NMIBC

Urology Times·Jan 19

Dr Galsky on the Current Roles of Biomarkers in Bladder Cancer

OncLive·Jun 10

Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence

Cureus·Jun 6

Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks

Nature·Jan 4

The current and future role of systemic therapy in non–muscle‐invasive bladder cancer

Wiley & Sons·Jun 29

View original report at Urology Times ↗

Fetching the latest headlines…